目的 探究銀丹心腦通軟膠囊聯(lián)合纈沙坦治療原發(fā)性高血壓的臨床療效。方法 選取2015年10月—2016年10月河南省信陽市第三人民醫(yī)院心血管內科收治的原發(fā)性高血壓患者201例，隨機分為對照組（100例）和治療組（101例）。對照組患者口服纈沙坦膠囊，1粒/次，1次/d。治療組在對照組的治療基礎上口服銀丹心腦通軟膠囊，2粒/次，3次/d。所有患者均連續(xù)治療8周。觀察兩組的臨床療效，比較兩組治療前后收縮壓、舒張壓、血壓變異性、血糖異常、血脂異常的變化情況。結果 治療后，對照組和治療組的總有效率分別為86.0%、97.0%，兩組比較差異有統(tǒng)計學意義（P< 0.05）。治療后，兩組患者收縮壓、舒張壓、收縮壓和舒張壓的血壓變異性均較治療前明顯降低，同組治療前后差異有統(tǒng)計學意義（P< 0.05）；治療后，治療組收縮壓、舒張壓、收縮壓和舒張壓的血壓變異性均顯著低于對照組，兩組比較差異有統(tǒng)計學意義（P< 0.05）。治療后，兩組患者血糖異常、血脂異常的例數和異常率均較治療前顯著降低，同組治療前后差異有統(tǒng)計學意義（P< 0.05）；治療后，治療組血糖異常、血脂異常的例數和異常率均低于對照組，兩組比較差異有統(tǒng)計學意義（P< 0.05）。對照組和治療組的不良反應發(fā)生率分別為23.0%、6.9%，兩組比較差異有統(tǒng)計學意義（P< 0.05）。結論 銀丹心腦通軟膠囊聯(lián)合纈沙坦治療原發(fā)性高血壓具有顯著的臨床療效，可降低患者血壓、血壓變異性，具有一定的臨床推廣應用價值。

Objective To explore the clinical efficacy of Yindan Xinnaotong Capsules combined with valsartan in treatment of primary hypertension. Methods Patients (201 cases) with primary hypertension in Department of Cardiovascular Medicine of Xinyang Third People's Hospital in Henan from October 2015 to October 2016 were randomly divided into control (100 cases) and treatment (101 cases) groups. Patients in the control group were po administered with Valsartan Capsules, 1 grain/time, once daily. Patients in the treatment group were po administered with Yindan Xinnaotong Capsules, 2 grains/time, three times daily. Patients in two groups were treated for 8 weeks. After treatment, the clinical efficacy was evaluated, and the changes of systolic blood pressure, diastolic blood pressure, blood pressure variability, abnormal blood glucose, dyslipidemia in two groups before and after treatment were compared. Results After treatment, the clinical efficacy in the control and treatment groups were 86.0% and 97.0%, respectively, and there was difference between two groups (P < 0.05). After treatment, systolic blood pressure, diastolic blood pressure, and blood pressure variability in two groups decreased statistically, and the difference was statistically significant in the same group (P < 0.05). After treatment, systolic blood pressure, diastolic blood pressure, and blood pressure variability in the treatment group were lower than those in the control group, and there was difference between two groups (P < 0.05). After treatment, the number of cases and the abnormal rate of abnormal blood glucose and dyslipidemia in two groups decreased statistically, and the difference was statistically significant in the same group (P < 0.05). After treatment, the number of cases and the abnormal rate of abnormal blood glucose and dyslipidemia in the treatment group were lower than those in the control group, and there was difference between two groups (P < 0.05). After treatment, the incidence of adverse reactions in the control and treatment groups were 23.0% and 6.9%, respectively, and there was difference between two groups (P < 0.05). Conclusion Yindan Xinnaotong Capsules combined with valsartan has a significant effect in treatment of primary hypertension, and can reduce the blood pressure and blood pressure variability, which has a certain clinical application value.